DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 129 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,385,743 | -9.7% | 1,209,571 | 0.0% | 19.76% | +35.1% |
| Q2 2023 | $17,030,760 | -8.9% | 1,209,571 | 0.0% | 14.63% | -5.3% |
| Q1 2023 | $18,687,872 | -5.7% | 1,209,571 | 0.0% | 15.44% | +7.6% |
| Q4 2022 | $19,824,869 | -11.4% | 1,209,571 | 0.0% | 14.35% | +8.1% |
| Q3 2022 | $22,377,000 | +40.7% | 1,209,571 | 0.0% | 13.28% | +28.9% |
| Q2 2022 | $15,906,000 | +41.9% | 1,209,571 | 0.0% | 10.30% | +86.5% |
| Q1 2022 | $11,213,000 | -5.1% | 1,209,571 | 0.0% | 5.53% | +29.1% |
| Q4 2021 | $11,818,000 | -71.2% | 1,209,571 | 0.0% | 4.28% | -63.9% |
| Q3 2021 | $41,101,000 | +24.0% | 1,209,571 | 0.0% | 11.86% | +39.4% |
| Q2 2021 | $33,140,000 | -38.9% | 1,209,571 | 0.0% | 8.51% | -32.6% |
| Q1 2021 | $54,237,000 | -21.4% | 1,209,571 | 0.0% | 12.62% | -20.9% |
| Q4 2020 | $69,030,000 | +11.2% | 1,209,571 | 0.0% | 15.95% | -36.2% |
| Q3 2020 | $62,051,000 | -14.1% | 1,209,571 | 0.0% | 25.00% | +20.6% |
| Q2 2020 | $72,236,000 | -15.9% | 1,209,571 | -42.0% | 20.73% | -19.3% |
| Q1 2020 | $85,910,000 | -33.9% | 2,086,723 | 0.0% | 25.70% | -8.9% |
| Q4 2019 | $129,878,000 | +24.5% | 2,086,723 | -32.1% | 28.22% | -10.6% |
| Q3 2019 | $104,360,000 | +12.8% | 3,074,825 | -25.1% | 31.57% | +27.3% |
| Q2 2019 | $92,548,000 | -2.8% | 4,104,140 | 0.0% | 24.81% | -5.0% |
| Q1 2019 | $95,257,000 | +10.6% | 4,104,140 | 0.0% | 26.10% | +10.4% |
| Q4 2018 | $86,146,000 | -45.8% | 4,104,140 | 0.0% | 23.65% | -18.2% |
| Q3 2018 | $158,912,000 | -1.6% | 4,104,140 | 0.0% | 28.92% | -25.8% |
| Q2 2018 | $161,498,000 | +96.4% | 4,104,140 | 0.0% | 38.98% | -12.2% |
| Q1 2018 | $82,247,000 | -11.6% | 4,104,140 | 0.0% | 44.41% | +2.1% |
| Q4 2017 | $93,041,000 | +19.4% | 4,104,140 | 0.0% | 43.52% | +20.3% |
| Q3 2017 | $77,938,000 | – | 4,104,140 | – | 36.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |